Join Jackie Hunter, CE Clinical and Strategic Partnerships and Board Director at BenevolentAI to discuss How Artificial Intelligence is revolutionising drug discovery and development.
Over the past few years there has been a significant increase in the application of artificial intelligence to the process of drug discovery and development in order to tackle the productivity and innovation challenges of the industry. At BenevolentAI we have been developing a platform that can impact drug discovery at multiple points along the process from novel target identification though to new chemical design and patient stratification. We have number of research programmes which have utilised our platform and have already shown it can make a significant impact in terms of both efficiency and effectiveness. Our platform is capable of creating new knowledge from vast quantities of biomedical information which enables us to identify new important mechanisms in diseases with high unmet medical need. In addition BenevolentAI chemists are able to use the platform to design better molecules, more cost effectively as well as using computer based de novo design.
Jackie Hunter is currently a Board Director of BenevolentAI, a UK unicorn company that uses artificial intelligence to disrupt the drug discovery and development process.. She has held numerous senior leadership positions in the pharmaceutical, biotechnology and innovation industries industries, working for a number of companies including Smithkline Beecham, GSK, Proximagen and latterly OI Pharma Partners, which she founded in 2010. Jackie served as CEO of the Biotechnology and Biological Sciences Research Council between 2013 and 2016. She is also a Fellow of the British Pharmacological Society and of the Academy of Medical Sciences. For her services to the pharmaceutical industry, she was awarded a CBE in 2010 Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She is a member of the Biomedical Advisory Board member for A* Singapore and a non-Executive Director of the UK Bioindustry Association.